Suven Life Sciences マネジメント

マネジメント基準チェック /24

Suven Life Sciencesの CEO はVenkat Jastiで、 Oct2004年に任命され、の在任期間は 20.08年です。は、会社の株式の0.001%を直接所有しており、その価値は₹ 266.07K 。経営陣と取締役会の平均在任期間はそれぞれ14.2年と10.5年です。

主要情報

Venkat Jasti

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	20.1yrs
CEOの所有権	0.001%
経営陣の平均在職期間	14.2yrs
取締役会の平均在任期間	10.5yrs

経営陣の近況

Recent updates

CEO報酬分析

Suven Life Sciences の収益と比較して、Venkat Jasti の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-₹1b
Jun 30 2024	n/a	n/a	-₹1b
Mar 31 2024	n/a	n/a	-₹1b
Dec 31 2023	n/a	n/a	-₹1b
Sep 30 2023	n/a	n/a	-₹1b
Jun 30 2023	n/a	n/a	-₹1b
Mar 31 2023	n/a	n/a	-₹1b
Dec 31 2022	n/a	n/a	-₹1b
Sep 30 2022	n/a	n/a	-₹940m
Jun 30 2022	n/a	n/a	-₹991m
Mar 31 2022	n/a	n/a	-₹1b
Dec 31 2021	n/a	n/a	-₹1b
Sep 30 2021	n/a	n/a	-₹1b
Jun 30 2021	n/a	n/a	-₹1b
Mar 31 2021	n/a	n/a	-₹722m
Dec 31 2020	n/a	n/a	-₹761m
Sep 30 2020	n/a	n/a	-₹745m
Jun 30 2020	n/a	n/a	-₹787m
Mar 31 2020	n/a	n/a	-₹942m
Dec 31 2019	n/a	n/a	₹28m
Sep 30 2019	n/a	n/a	₹1b
Jun 30 2019	n/a	n/a	₹871m
Mar 31 2019	₹58m	₹29m	-₹239m
Mar 31 2018	₹47m	₹25m	₹1b

報酬と市場: Venkatの総報酬がIndian市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Venkatの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Venkat Jasti (75 yo)

20.1yrs

在職期間

Mr. Venkateswarlu Jasti, also known as Venkat, M.Pharm. M.S., has been the Managing Director and Executive Chairman of the Board of Suven Life Sciences Limited since November 01, 2024. He is Member of Advi...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Venkateswarlu Jasti	CEO, MD & Executive Chairman	20.1yrs	データなし	0.0010% ₹ 266.1k
Sudharani Jasti	Whole-Time Director	35.7yrs	₹9.99m	0.70% ₹ 184.6m
M. Kumar	Chief Financial Officer	4.8yrs	データなし	データなし
Kundan Jha	Company Secretary & Compliance Officer	less than a year	データなし	データなし
Kalyani Jasti	President of US Operations	14.2yrs	データなし	0.00046% ₹ 121.2k

14.2yrs

平均在職期間

70yo

平均年齢

経験豊富な経営陣: 530239の経営陣は経験豊富で経験豊富です（平均在職期間は14.2年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Venkateswarlu Jasti	CEO, MD & Executive Chairman	35.7yrs	データなし	0.0010% ₹ 266.1k
Sudharani Jasti	Whole-Time Director	35.7yrs	₹9.99m	0.70% ₹ 184.6m
Seyed Hasnain	Non-Independent & Non-Executive Director	14.6yrs	₹200.00k	データなし
Santanu Mukherjee	Independent Non-Executive Director	6.5yrs	₹250.00k	データなし
Jasthi Ananthasai Padmaja	Independent Non-Executive Director	6yrs	₹110.00k	データなし
Vajja Rao	Independent Director	less than a year	データなし	データなし

10.5yrs

平均在職期間

70yo

平均年齢

経験豊富なボード: 530239の取締役会は経験豊富で経験豊富です ( 10.5年の平均在任期間)。

Suven Life Sciences マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Suven Pharma Announces Board Changes

Suven Life Sciences Limited Announces Step Down of Vaidheesh Annaswamy as Executive Chairperson and Director

Suven Life Sciences Limited, Annual General Meeting, Aug 02, 2024

Suven Life Sciences Limited Approves the Retirement of Gopalakrishna Muddusetty as Non-Executive Independent Director, Effective March 31, 2024

Suven Pharma Appoints Sudhir Kumar Singh as CEO

Suven Life Sciences Limited, Annual General Meeting, Aug 05, 2023

Recent updates

New major risk - Financial position

Second quarter 2025 earnings released: ₹2.27 loss per share (vs ₹0.58 loss in 2Q 2024)

Suven Life Sciences Limited to Report Q2, 2025 Results on Nov 12, 2024

Suven Pharma Announces Board Changes

Suven Life Sciences Limited Announces Step Down of Vaidheesh Annaswamy as Executive Chairperson and Director

Suven Life Sciences Announces Positive Topline Results from Phase-2A Proof-Of-Concept Signal Detection Open Label Study of Ropanicant (Suvn-911) for the Treatment of Moderate to Severe Major Depressive Disorder

Suven Life Sciences Announces FDA Acceptance of Investigational New Drug (IND) and Grant of Study May Proceed Letter to Initiate Phase-1 Clinical Trial of SUVN-I6107

New minor risk - Share price stability

First quarter 2025 earnings released: ₹1.29 loss per share (vs ₹1.10 loss in 1Q 2024)

Suven Life Sciences Limited to Report Q1, 2025 Results on Aug 05, 2024

Full year 2024 earnings released: ₹4.82 loss per share (vs ₹6.63 loss in FY 2023)

Suven Life Sciences Limited, Annual General Meeting, Aug 02, 2024

Full year 2024 earnings released: ₹4.82 loss per share (vs ₹6.63 loss in FY 2023)

Third quarter 2024 earnings released: ₹1.92 loss per share (vs ₹2.90 loss in 3Q 2023)

Suven Life Sciences Limited Approves the Retirement of Gopalakrishna Muddusetty as Non-Executive Independent Director, Effective March 31, 2024

Suven Life Sciences Limited to Report Q3, 2024 Results on Jan 30, 2024

New major risk - Share price stability

Suven Life Sciences Limited to Report Q4, 2024 Results on May 15, 2024

Second quarter 2024 earnings released: ₹0.58 loss per share (vs ₹1.59 loss in 2Q 2023)

New minor risk - Share price stability

Suven Life Sciences Limited to Report Q2, 2024 Results on Nov 04, 2023

Suven Pharma Appoints Sudhir Kumar Singh as CEO

Suven Life Sciences Limited to Report Q1, 2024 Results on Aug 08, 2023

Full year 2023 earnings released: ₹6.63 loss per share (vs ₹9.05 loss in FY 2022)

Suven Life Sciences Completes Enrollment of Patients to the Phase-2, Proof of Concept Clinical Study of Samelisant (SUVN-G3031) for the Treatment of Narcolepsy with or Without Cataplexy in USA and Canada

Suven Life Sciences Limited, Annual General Meeting, Aug 05, 2023

Full year 2023 earnings released: ₹6.63 loss per share (vs ₹9.57 loss in FY 2022)

Third quarter 2023 earnings released: ₹2.90 loss per share (vs ₹2.65 loss in 3Q 2022)

Suven Life Sciences Limited to Report Q3, 2023 Results on Feb 02, 2023

Suven Life Sciences Limited Announces the Randomization of First Patient in the Phase-3 Global Clinical Trial of Masupirdine for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type

Price target decreased to ₹306

Insufficient new directors

Second quarter 2023 earnings released

Suven Life Sciences Limited to Report Q2, 2023 Results on Nov 08, 2022

Suven Life Sciences Limited Declares Special Dividend for the Financial Year 2022-23, Payable on and from September 20, 2022

Suven Life Sciences Limited to Report Q1, 2023 Results on Jul 26, 2022

Full year 2022 earnings released: ₹9.57 loss per share (vs ₹5.67 loss in FY 2021)

Suven Life Sciences Limited Declares One-Time Special Dividend for the Financial Year 2021-22, Payable on and from 25 May, 2022

Full year 2022 earnings released: ₹9.57 loss per share (vs ₹5.67 loss in FY 2021)

Suven Life Sciences Limited, Annual General Meeting, Aug 04, 2022

Suven Life Sciences Limited to Report Q4, 2022 Results on May 07, 2022

Price target decreased to ₹306

Insufficient new directors

Suven Life Sciences Limited Declares Interim Dividend, Payable on and from 22 February 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released: ₹2.22 loss per share (vs ₹1.23 loss in 2Q 2021)

Price target decreased to ₹306

Full year 2021 earnings released: ₹5.67 loss per share (vs ₹7.40 loss in FY 2020)

Price target increased to ₹472

Full year 2021 earnings released: ₹5.67 loss per share (vs ₹7.40 loss in FY 2020)

Suven Life Sciences Limited announced that it has received INR 369.10425 million in funding from Jasti Family Trust

Independent Non-Executive Director has left the company

Third quarter 2021 earnings released: ₹1.92 loss per share (vs ₹1.79 loss in 3Q 2020)

Suven Life Sciences Limited to Report Q3, 2021 Results on Jan 28, 2021

New 90-day high: ₹57.90

First half earnings released

New 90-day high: ₹56.45

Insider recently bought ₹1.0m worth of stock

New 90-day high - ₹54.50

Suven Life Sciences Limited to Report Q1, 2021 Results on Aug 17, 2020

First quarter earnings released

New 90-day high - ₹48.55

Suven Life Sciences Limited to Report Q1, 2021 Results on Aug 11, 2020

Price target raised to ₹537

Suven Life Sciences Limited(BSE:530239) dropped from S&P Global BMI Index

CEO報酬分析

CEO（最高経営責任者

マネジメント基準チェック /24